Methadone to Treat Painful Chemotherapy-induced Peripheral Neuropathy - Trial NCT05786599
Access comprehensive clinical trial information for NCT05786599 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of British Columbia and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of British Columbia
Timeline & Enrollment
Phase 2
Jul 01, 2023
Aug 01, 2024
Primary Outcome
Efficacy of methadone to reduce the reported average pain intensity using the Brief Pain Inventory-Short Form questionnaire.
Summary
Chemotherapy induced peripheral neuropathy (CIPN) is a painful and disabling nerve pain that
 can be caused from common types of chemotherapy used to treat cancer. It can affect up to 70%
 of people who receive chemotherapy for months or even life-long. CIPN causes
 glove-and-stocking distribution of nerve-pain, weakness, lower quality of life, lower
 ability to do day to day tasks such as walking and writing, and other symptoms.
 
 Duloxetine is the only recommended medication by national and international groups such as
 the American Society of Oncology to treat painful CIPN. However, studies show it only has
 small benefit; for example, the largest study showed it only reduces pain by 0.73 out of 10
 points compared to placebo.
 
 Another promising medication in theory and practice is methadone. It is a very well studied
 and commonly used pain medication from a class called opioids. However, it does have unique
 qualities that make it more effective to treat nerve pain when compared to other opioids like
 morphine and fentanyl. Furthermore, studies show it may develop less tolerance in the body
 over time when compared to other opioids; this is helpful as many develop lifelong CIPN and
 therefore may benefit from lifelong pain medication. Methadone has not been studied in CIPN.
 
 This study is a pilot clinical trial to assess the ability of methadone to lower the pain
 caused by CIPN. It will help determine if it is feasible (ie. a good idea) to conduct a much
 larger study to absolutely determine if methadone is able to treat painful CIPN. In this
 pilot study, participants will receive methadone three times a day for 5 weeks. They will be
 followed virtually or in-person weekly for 5 weeks where they will answer brief
 questionnaires which will help determine the effect of their treatment on their pain and
 their dose will increase until their pain is hopefully controlled.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05786599
Non-Device Trial